CORT News Alert Corcept Therapeutics Inc (CORT) 3.09 12/16/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Corcept Therapeutics Inc (CORT) 3.09 $CORT

Will Corcept (CORT) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 10:23AM CST
Will Corcept (CORT) Continue to Surge Higher?
CORT: 3.09 (+0.12)

Moving Average Crossover Alert: Corcept Therapeutics (CORT) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 8:27AM CST
Moving Average Crossover Alert: Corcept Therapeutics (CORT)
CORT: 3.09 (+0.12)

Global Cushing's Syndrome Therapeutics Market 2015-2019: Key Vendors are Corcept Therapeutics, HRA Pharma and Novartis
M2 - Thu Nov 20, 5:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/wvdxbs/global_cushings) has announced the addition of the "Global Cushing's Syndrome Therapeutics Market 2015-2019" report to their offering. One major trend upcoming in this market is the increase in public awareness of Cushing's syndrome. This is expected to lead to an increase in the number of treatment-seeking patients, thereby giving rise to the consumption of medications. According to the report, the major driving factor of the market is the presence of a huge unmet need in this rare disease area. Few FDA-approved drugs are available, and the use of off-label drugs can cause several adverse effects. Thus, drug makers have the opportunity to produce therapies which can give them an edge over others and seize a major portion of the total market. Further, the report states that the adverse effects of the drugs used to treat Cushing's syndrome are a major challenge to the growth of the market. Patient incompatibility leads to an increase in the churn-out rate of the patients from the treatment. This results in restraining the market growth. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Product Profiles 05. Market Research Methodology 06. Introduction 07. Disease Overview 08. Market Landscape 09. Market Segmentation by Class of Drugs 10. Market Segmentation by Route of Administration 11. Market Segmentation by Dosage Form 12. Geographical Segmentation 13. Buying Criteria 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Pipeline Portfolio 22. Key Vendor Analysis 23. Other Reports in this Series Companies Mentioned: - Corcept Therapeutics - HRA Pharma - Novartis - Aspireo Pharmaceuticals - Cortendo - ElexoPharm - Ipsen - Isis Pharmaceuticals - Orphagen Pharmaceuticals - Samaritan Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/wv...l_cushings
ISIS: 54.94 (-1.99), CORT: 3.09 (+0.12), NVS: 91.65 (+0.01)

Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 7:18PM CST

CORT: 3.09 (+0.12)

Corcept posts 3Q loss
Automated Insights - Tue Nov 04, 5:15PM CST
MENLO PARK, Calif. (AP) _ Corcept Therapeutics Inc. (CORT) on Tuesday reported a loss of $6 million in its third quarter.
CORT: 3.09 (+0.12)

Corcept Therapeutics beats by $0.03, misses on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 3:28PM CST

CORT: 3.09 (+0.12)

Corcept Therapeutics Announces Third Quarter 2014 Financial Results and Provides Corporate Update
Marketwired - Tue Nov 04, 3:09PM CST
Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, oncologic and psychiatric disorders, today reported its financial results for the quarter ended September 30, 2014. The company also provided an update on its clinical programs and revised its 2014 revenue guidance.
CORT: 3.09 (+0.12)

Notable earnings after Tuesday's close
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 4:35PM CST

AMRS: 2.14 (-0.01), ITRI: 39.59 (+0.27), AWAY: 28.28 (-1.07), OKE: 44.30 (-0.02), HR: 26.73 (-0.01), NYMT: 7.89 (+0.02), OCLR: 1.92 (+0.03), ENPH: 12.46 (+0.08), ADEP: 8.00 (-0.03), CBSO: 27.51 (+0.58), NSTG: 13.56 (-0.25), MITT: 18.13 (-0.76), CRTO: 37.84 (+0.53), FOXA: 36.21 (-0.29), OKS: 38.23 (-0.16), JMBA: 13.39 (-0.18), IVR: 15.31 (-0.18), CSU: 24.03 (-0.29), MYGN: 33.02 (-0.41), JIVE: 5.33 (-0.03), GAS: 50.42 (-0.23), COUP: 15.39 (+0.08), NRP: 9.59 (+1.19), MOSY: 1.65 (-0.03), COHR: 58.60 (-0.05), DOX: 45.78 (-0.12), CKEC: 24.91 (-0.59), OAS: 14.23 (+2.01), PAYC: 26.59 (+2.35), PCYC: 129.56 (+1.12), AXLL: 37.22 (-1.06), NP: 56.01 (-0.32), BIRT: 6.57 (+0.02), ATVI: 19.38 (-0.64), EXAM: 38.20 (-0.96), P: 16.90 (-0.29), JAZZ: 159.65 (-2.95), PBPB: 11.88 (+0.22), EXEL: 1.31 (-0.05), CERS: 4.78 (+0.14), DVN: 54.10 (+1.44), FEYE: 27.72 (-0.84), CHUY: 19.04 (-0.78), FRGI: 55.82 (-4.46), GHDX: 30.54 (+0.01), PACD: 4.46 (-0.04), BIO: 116.03 (+0.28), BIOL: 2.63 (-0.04), JKHY: 61.39 (-0.36), KAR: 33.79 (-0.35), CDXS: 2.28 (-0.04), MPO: 1.42 (+0.26), FANG: 55.84 (+2.44), CORT: 3.09 (+0.12), CALD: 14.76 (unch)

Corcept reports November 4
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 3:56PM CDT

CORT: 3.09 (+0.12)

Corcept Therapeutics to Announce Third Quarter Financial Results and Host Conference Call
Marketwired - Tue Oct 28, 3:08PM CDT
Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 4, 2014. The Company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
CORT: 3.09 (+0.12)

Corcept Therapeutics (CORT) Jumps: Stock Rises 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 8:32AM CDT
Corcept Therapeutics Incorporated (CORT) was a big mover last session, as the company saw its shares rise more than 6% on the day.
CANF: 3.35 (-0.17), AMPE: 3.29 (-0.07), CEMP: 18.17 (-0.26), CORT: 3.09 (+0.12)

Heartbeat Wins 8 New Awards, Including CLIO Silver & MM&M Gold
Business Wire - Mon Oct 13, 11:01AM CDT
Heartbeat Ideas and Heartbeat West, natively-digital, full-service, marketing innovation agencies, have won eight new awards over the last few weeks, bringing to 16 the total number of industry awards in this record-setting year for the company. Heartbeat's honored work includes Corcept Therapeutics' Korlym "Cushing's Connection" Integrated Campaign, XenoPort's HORIZANT "End the Bedtime Battle" Integrated Campaign, and Sientra's "Feel So Good" Online Media Campaign.
CORT: 3.09 (+0.12)

Esperion Therapeutics Slumps: ESPR Falls 6.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 7:48AM CDT
Esperion Therapeutics has been witnessing a flat trend in its current year earnings estimate and its share price has been falling for past 24 hours
ESPR: 34.52 (-0.48), AMPE: 3.29 (-0.07), CEMP: 18.17 (-0.26), CORT: 3.09 (+0.12)

PTC Therapeutics (PTCT) Crumbles: Stock Falls by 5.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 7:42AM CDT
PTC Therapeutics stock fell over 5% last trading session, continuing its recent downtrend
LCI: 42.70 (-1.35), PTCT: 48.42 (-2.03), CEMP: 18.17 (-0.26), CORT: 3.09 (+0.12)

Publicis Healthcare Agencies and Leaders Honored at the 2014 MM&M Awards
PRWeb - Mon Oct 06, 7:04AM CDT
Publicis Healthcare Communications Group (PHCG), the world's largest health-oriented communications network, today announced four of its network agencies were honored at the 2014 MM&M Awards, making Publicis Healthcare the most winning agency network recognized. Additionally, Matt McNally, President, Publicis Health Media, received the Silver Agency Marketer of the Year Award, and Allyson Mariani, Media Planner, Publicis Health Media, was honored with the Gold Young Marketer of the Year Award. PHCG agencies picked up nine MM&M awards, including: Agency Marketer of the Year (Silver MM&M Award): Matt McNally, President, Publicis Health Media Young Marketer of the Year (Gold MM&M Award): Allyson Mariani, Media Planner, Publicis Health Media Best Use of Direct Marketing (Gold MM&M Award): Heartbeat West and Sientra for "Feel So Good" Best Use of Direct Marketing (Silver MM&M Award): Digitas Health LifeBrands and Rebif(R) (interferon beta-1a) by EMD Serono, Inc. and Pfizer Inc for "Rebif Information Kit" Best Branded Website for Healthcare Professionals (Gold MM&M Award): Publicis Life Brands Medicus and Chattem, a Sanofi company for "Nasacort Allergy 24HR Launch Website" Best Use of Social Media (Silver MM&M Award): Heartbeat Ideas, Heartbeat West, and Corcept Therapeutics for "Cushing's Connection" Best Medical Digital Initiative for Consumers (Silver MM&M Award): Heartbeat Ideas, Heartbeat West, and Corcept Therapeutics for "Cushing's Connection" Best Philanthropic Campaign (Gold MM&M Award): Saatchi & Saatchi Wellness and Crossroads Community for "Crossroads Community Street Fare" Best TV Advertising Campaign (Gold MM&M Award): Saatchi & Saatchi Wellness and AbbVie (Humira) for "Inside The Circle"
CORT: 3.09 (+0.12)

Cortendo AB to Present at the 14th Annual BIOTECH in Europe Forum in Basel September 30, 2014
Business Wire - Mon Sep 29, 4:54AM CDT
Cortendo AB (OAX:CORT)
CORT: 3.09 (+0.12)

5 Stocks to Trade for Big Breakout Gains
at The Street - Mon Sep 22, 10:45AM CDT
These stocks look ready to break out and trade higher from current levels.
TSLA: 197.81 (-6.23), FLL: 1.47 (+0.03), SYRX: 1.02 (-0.04), GOOGL: 498.16 (-17.68), CORT: 3.09 (+0.12), GSAT: 2.69 (-0.01)

Cortendo AB: Interim Report, Q2 and H1 2014
Business Wire - Tue Aug 26, 2:14AM CDT
Cortendo AB (OSE:CORT)
CORT: 3.09 (+0.12)

Investors look to Lighten Up on Shares of Corcept Therapeutics, Shares Down 8.8% (CORT)
Comtex SmarTrend(R) - Thu Aug 21, 12:42PM CDT
Corcept Therapeutics (NASDAQ:CORT) is one of today's worst performing low-priced stocks, down 8.8% to $2.69 on 1.1x average daily volume. Corcept Therapeutics has traded 248,000 shares thus far today, vs. average volume of 226,000 shares per day. The stock has underperformed the Dow (-8.8% to the Dow's 0.5%) and underperformed the S&P 500 (-8.8% to the S&P's 0.3%) during today's trading.
CORT: 3.09 (+0.12)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Minnesota Giving Record Signals a Stressed Safety Net

Updated Category News Views 63

Thirty-eight million dollars landing in one day is no small civic heartbeat. Minnesota’s Give to the Max Day brought in a record $38.4 million in 2026 for nearly 6,000 nonprofits and schools, edging past the $37.8 million raised in 2025. More than 65,000 people gave. That deserves a clear-eyed nod, not a cynical shrug. Still, the number carries two messages at once. It...

Continue Reading
Tampa General's Food Bet Earns a 2026 Innovation Award

Updated Category News Views 27

Hospital meals have long been the punchline nobody bothered to fix, which is why Tampa General Hospital's latest recognition deserves a closer look. The not-for-profit academic health system was named the 2026 Inno Pick by the Tampa Bay Business Journal for its Food as Medicine initiative, its fifth straight year landing among the publication's Inno Award honorees. Awards...

Continue Reading
Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 79

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading
COP31 Tests Whether Climate Warnings Move Power Systems

Updated Category News Views 123

A weather alert that never reaches the control room is just expensive wallpaper. That was the useful, unsentimental thread running through a COP31 side event in Ankara on November 13: climate diplomacy is not worth much if grid operators, project owners and financiers do not change what they do when the forecast turns ugly. Implementation Means Changing Operations COP31...

Continue Reading
Why Dent Repair Estimates Need More Than a Simple Ruler

Updated Category News Views 118

A dent can look harmless in a parking-lot glare and still turn into a stubborn repair job once somebody examines the metal properly. That is the useful, unglamorous point Jason Phelps of Magic Dent makes in a HelloNation article: visible diameter is not a verdict. Anybody shopping for vehicle repairs, managing fleet costs, or watching the collision-service ecosystem ought...

Continue Reading
Teva’s R&D Exit Puts Disclosure Questions in Focus

Updated Category News Views 61

An abrupt departure in the drug business is never just an HR memo. Teva Pharmaceutical Industries shares reportedly dropped about 8.74% after Eric Hughes, the company’s executive vice president of Global R&D and chief medical officer, left effective immediately. That kind of move rattles investors because R&D leadership is not decorative furniture at a pharmaceutical...

Continue Reading
Ampace Targets AI Data Centre UPS Safety Needs in Paris

Updated Category News Views 109

Backup power gets interesting only after the grid has disappointed everybody. At Data Centre World Paris 2026, Ampace put its attention on that ugly, split-second handoff: utility power drops, a UPS has to catch the load immediately, and nobody operating an AI data centre gets to shrug if it does not. A Narrow Job With Brutal Consequences The company showcased its PU200...

Continue Reading
ADFW 2026 Builds a Bigger Stage for Global Capital

Updated Category News Views 30

Abu Dhabi is not merely booking conference rooms this December; it is assembling a very deliberate display of financial muscle. Abu Dhabi Finance Week runs from 7 to 10 December 2026, and ADGM says its fifth edition will carry its largest-ever programme of partner-led activity. That is a promotional claim, sure, but the partner list is substantial enough that investors...

Continue Reading
BioVersys AlpE Data Offers a Measured TB Treatment Signal

Updated Category News Views 119

Tuberculosis drug development rarely hands anybody a clean victory lap, and BioVersys' latest readout is no exception. The completed 14-day Phase 2a ENABLE study gives alpibectir plus ethionamide, known as AlpE, a credible early clinical signal in newly diagnosed drug-sensitive pulmonary TB. That matters. It does not, however, settle the far larger question of whether...

Continue Reading
Straub's Court Win Raises Cost of Seven-Year Fight

Updated Category News Views 68

Seven years of courtroom smoke over an under-$80,000 lien is the sort of mess that makes any business owner grind his teeth. Palm Beach Polo says its president, Glenn Straub, has again prevailed against Jessica Nicodemo in Palm Beach County, following an earlier Broward County dismissal of related claims. The company also says Vice President Sal Spano received a directed...

Continue Reading

Top 5 Most Recently Viewed Articles

Allstream Insiders Unveils Industry Talks for Energy Pros

Updated Category News Views 294

Allstream Insiders Launches New Industry Talks Platform HOUSTON -- Allstream Insiders has rolled out an innovative platform called Industry Talks, specifically tailored for professionals within the energy sector. This initiative is designed to offer vital insights and a venue for sharing ideas that resonate in the New Energy markets. Focus on Career Growth and Skills A...

Continue Reading
Exploring Orexo's Pharmaceutical Innovations and IP Strategies

Updated Category News Views 130

Orexo's Insights on Pharmaceutical IP Strategies Orexo, a prominent player in the pharmaceutical industry, is poised to share its extensive knowledge in protecting intellectual property (IP) during an upcoming seminar. This event, organized in collaboration with esteemed law firms Potter Clarkson LLP and Steptoe LLP, aims to equip pharmaceutical companies, biotech firms,...

Continue Reading
Lindblad Expeditions Holdings Plans Tender Offer for Notes

Updated Category News Views 156

Lindblad Expeditions Holdings Begins Tender Offer for Senior Notes Lindblad Expeditions Holdings, Inc. (NASDAQ: LIND) has recently announced the pricing terms of its ongoing tender offer aimed at acquiring any and all of its outstanding 6.750% Senior Secured Notes due 2027. This notable initiative is executed through its wholly-owned subsidiary, Lindblad Expeditions, LLC....

Continue Reading
Key Economic Reports to Influence Markets This Thursday

Updated Category News Views 103

Key Economic Reports to Influence Markets This Thursday As traders gear up for another pivotal day in the financial markets, several key economic reports are expected to be released. These reports could significantly impact market dynamics and sway investor sentiment. This Thursday’s lineup includes essential data on the services sector, jobless claims, and factory...

Continue Reading
Investigation Launch: Zeta Global Holdings Corp Under Scrutiny

Updated Category News Views 160

Zeta Global Holdings Corp (NYSE: ZETA) is stepping into turbulent waters with an intense investigation hovering over its officers and directors regarding possible breaches of fiduciary duty. For shareholders who’ve been riding the wave since at least February 2022, this isn’t just another corporate footnote; it’s a pressing signal that deserves attention. With the...

Continue Reading